The KRT4 antibody targets keratin 4 (KRT4), a type II intermediate filament protein encoded by the *KRT4* gene. Keratins are crucial structural components of epithelial cells, providing mechanical stability and resilience. KRT4 pairs with type I keratins (e.g., KRT13) to form heteropolymers, primarily expressed in non-cornified stratified squamous epithelia, such as the oral mucosa, esophagus, and glandular ducts. Its expression is tightly regulated during epithelial differentiation, making it a marker for specific epithelial subtypes.
KRT4 antibodies are widely used in research and diagnostics to study epithelial cell biology, tissue development, and pathological conditions. Reduced or aberrant KRT4 expression is associated with malignancies, including head/neck and esophageal cancers, serving as a potential biomarker for tumor progression. Additionally, mutations in *KRT4* are linked to hereditary mucosal disorders like white sponge nevus, where antibodies aid in detecting abnormal keratin aggregates.
In immunohistochemistry, KRT4 antibodies help identify epithelial origin in tumors and assess tissue architecture. Their specificity enables applications in understanding cellular stress responses, wound healing, and epithelial-mesenchymal transition mechanisms. Overall, KRT4 antibodies are vital tools for exploring epithelial integrity, disease mechanisms, and diagnostic utility in clinical pathology.